Statement: By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.
Primary_evidence: Outcome Measurement:    Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer   The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.   Time frame: At 48 weeks Results 1:    Arm/Group Title: Everolimus and Exemestane   Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.   Overall Number of Participants Analyzed: 49   Measure Type: Number   Unit of Measure: participants  Patients with measurable disease at baseline: 39   Patients with non-measurable disease at baseline: 10   Best at WK 48 - Complete Response (CR): 0   Best at WK 48 - Partial Response (PR): 7   Best at WK 48 - Stable Disease (SD): 18   Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8